{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T18:33:54Z","timestamp":1786905234520,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To examine the albuminuria\u2010lowering effect of exenatide once weekly (EQW) compared with active glucose\u2010lowering comparators in patients with type 2 diabetes and elevated urinary albumin\u2010to\u2010creatinine ratio (uACR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Six randomized double\u2010blind and open\u2010label phase III studies were pooled in a\n                      <jats:italic>post hoc<\/jats:italic>\n                      , exploratory analysis to evaluate the efficacy and safety of EQW versus non\u2010glucagon\u2010like peptide\u20101 receptor agonist comparators in patients with type 2 diabetes and baseline uACR \u226530\u2009mg\/g. Treatment groups were EQW versus all comparators pooled. Efficacy outcomes were percent change from baseline to week 26\/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics were generally similar between the two treatment groups (EQW: N = 194, all comparators: N = 274). Relative to the comparator group, EQW changed albuminuria by \u221226.2% (95% confidence interval [CI] \u221239.5 to \u221210). Similar improvements were observed with EQW versus oral glucose\u2010lowering drugs (\u221229.6% [95% CI \u221247.6 to \u22125.3) or insulin (\u221223.8% [95% CI \u221241.8 to \u22120.2]). The effect of EQW on uACR was independent of baseline renin\u2010angiotensin system inhibitor usage. Adjusted mean decreases in HbA1c, SBP and body weight were more pronounced in the EQW versus the comparator group. Adjustment for changes in HbA1c, eGFR and SBP did not substantially affect the uACR\u2010lowering effect of EQW. When also adjusting for changes in body weight, the uACR\u2010lowering effect was reduced to (\u221213.0% [95% CI \u221229.9 to 7.8]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Exenatide once weekly reduced uACR in patients with type 2 diabetes and elevated albuminuria compared to commonly used glucose\u2010lowering drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14067","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T02:06:21Z","timestamp":1587693981000},"page":"1556-1566","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-3259","authenticated-orcid":false,"given":"Annemarie B.","family":"van der Aart \u2010 van der Beek","sequence":"first","affiliation":[{"name":"Clinical Pharmacy and Pharmacology University of Groningen  Groningen The Netherlands"},{"name":"Clinical Pharmacy Martini Hospital  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"van Raalte","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Department of Internal Medicine Amsterdam UMC location VUMC  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8703-0522","authenticated-orcid":false,"given":"Cristian","family":"Guja","sequence":"additional","affiliation":[{"name":"Carol Davila University of Medicine and Pharmacy  Bucharest Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Hoogenberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Martini Hospital  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Suchower","sequence":"additional","affiliation":[{"name":"Kelly Services  Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Hardy","sequence":"additional","affiliation":[{"name":"Clinical Metabolism, Late\u2010stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8380-9766","authenticated-orcid":false,"given":"C. David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[{"name":"Clinical Metabolism, Late\u2010stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&amp;D AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacology University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report.2017.https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf. Accessed January 17 2020."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.07.005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666151223093841"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.123"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60406-0"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1107"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12908"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.07.007"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1333"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1065"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30268-7"},{"issue":"1","key":"e_1_2_8_21_1","article-title":"FP482EGFR loss with glucagon\u2010like PEPTIDE\u20101 (GLP\u20101) analogue treatment: data from sustain 6 and leader","volume":"34","author":"Perkovic V","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5301"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-1-200601030-00006"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/608397"},{"issue":"5","key":"e_1_2_8_30_1","first-page":"964","article-title":"Incidence of end\u2010stage renal disease following bariatric surgery in the Swedish obese subjects study","volume":"42","author":"Shulman A","year":"2018","journal-title":"Int J Obes 2005"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30080-4"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.14067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:12:18Z","timestamp":1761869538000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/dom.14067"],"URL":"https:\/\/doi.org\/10.1111\/dom.14067","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14067\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14067\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14067\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14067\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14067\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14067\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14067\/v1\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"2020-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}